rs112115472 - RBMX2P4 - ETV1
Magnitude 4.5 · 1 study on file
Reported associations
-
Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02 - Unknown journal (n.d.) · Unknown authors · PubMed 30850646
ABSTRACT: Frontal fibrosing alopecia (FFA) is a recently described inflammatory and scarring type of hair loss affecting almost exclusively women. Despite a dramatic recent increase in incidence the aetiopathogenesis of FFA remains unknown. We undertake genome-wide association studies in females from a UK cohort, comprising 844 cases and 3,760 controls, a Spanish cohort of 172 cases and 385 controls, and perform statistical meta-analysis. We observe genome-wide significant association with FFA at four genomic loci: 2p22.2, 6p21.1, 8q24.22 and 15q2.1. Within the 6p21.1 locus, fine-mapping indicates that the association is driven by the HLA-B*07:02 allele. At 2p22.1, we implicate a putative causal missense variant in CYP1B1, encoding the homonymous xenobiotic- and hormone-processing enzyme.
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
Discuss FFA risk and preventive options with dermatologist Moderate
Genetic susceptibility to FFA identified; early professional discussion may guide assessment strategy
Mention variant risk when next seeing dermatologist; ask about monitoring frequency
Screening
-
Dermatological screening for frontal fibrosing alopecia Moderate
Genetic variant rs112115472 confers 2.66-fold increased risk for FFA; early detection enables timely intervention
Dermatological assessment at baseline and annually if at-risk or symptomatic